Aptevo Therapeutics Inc.
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -38.59% | -46.88% | -42.91% | -246.07% | -316.91% |
| Total Depreciation and Amortization | -37.92% | -35.13% | -38.68% | -40.86% | -37.07% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -51.48% | -32.66% | -14.13% | 105.97% | 106.86% |
| Change in Net Operating Assets | -136.96% | -262.28% | -200.57% | -43.28% | 35.77% |
| Cash from Operations | -102.77% | -87.49% | -85.87% | -102.37% | 44.20% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 100.00% | 100.00% | 71.74% |
| Issuance of Common Stock | 64.63% | -7.72% | 32.41% | -7.77% | 36.65% |
| Repurchase of Common Stock | 90.00% | 62.50% | 62.50% | 75.00% | -150.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 99.90% | -- |
| Cash from Financing | 160.00% | 33.20% | 176.57% | 1,660.18% | 329.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -42.88% | -227.70% | -44.27% | -38.07% | 75.78% |